- Home
- JLS vs MRK Comparison
JLS vs MRK Comparison
Compare JLS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- MRK
- Stock Information
- Founded
- JLS 2009
- MRK 2000
- Country
- JLS United States
- MRK United States
- Employees
- JLS N/A
- MRK N/A
- Industry
- JLS Investment Managers
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- JLS Finance
- MRK Health Care
- Exchange
- JLS Nasdaq
- MRK Nasdaq
- Market Cap
- JLS 103.4M
- MRK 218.8B
- IPO Year
- JLS N/A
- MRK N/A
- Fundamental
- Price
- JLS $18.66
- MRK $88.04
- Analyst Decision
- JLS
- MRK Buy
- Analyst Count
- JLS 0
- MRK 15
- Target Price
- JLS N/A
- MRK $105.14
- AVG Volume (30 Days)
- JLS 26.6K
- MRK 12.1M
- Earning Date
- JLS 01-01-0001
- MRK 10-30-2025
- Dividend Yield
- JLS 9.33%
- MRK 3.70%
- EPS Growth
- JLS N/A
- MRK 20.41
- EPS
- JLS N/A
- MRK 6.49
- Revenue
- JLS N/A
- MRK $63,616,000,000.00
- Revenue This Year
- JLS N/A
- MRK $1.76
- Revenue Next Year
- JLS N/A
- MRK $5.11
- P/E Ratio
- JLS N/A
- MRK $13.49
- Revenue Growth
- JLS N/A
- MRK 1.82
- 52 Week Low
- JLS $15.48
- MRK $73.31
- 52 Week High
- JLS $17.97
- MRK $106.62
- Technical
- Relative Strength Index (RSI)
- JLS 42.67
- MRK 60.20
- Support Level
- JLS $18.56
- MRK $86.91
- Resistance Level
- JLS $18.79
- MRK $88.79
- Average True Range (ATR)
- JLS 0.21
- MRK 1.45
- MACD
- JLS -0.01
- MRK 0.14
- Stochastic Oscillator
- JLS 35.45
- MRK 86.67
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).